Abstract:Depression is highly prevalent in individuals with diabetes and further increases the risk of the development of diabetes 1. Accumulating evidence shows that a diagnosis of type 2 diabetes could increase the risk of incident depression and aggravate a more severe course of depression 2. Recently, we read with great interest the article entitled ‘Antidepressant-like Effect of Insulin in Streptozotocin-induced Type 2 Diabetes Mellitus Rats' by Sestile et al. 3, in which the authors using streptozotocin (STZ)-induced type 2 diabetes mellitus rats demonstrated that daily treated for consecutive 21 days with insulin significantly decreased immobility time of forced swimming test (FST), indicating that insulin, a peptide hormone secreted by β cells in the pancreas, which is intended to treat diabetes by regulation of the metabolism of carbohydrates and fats via improving the consumption of glucose from the blood to skeletal muscles 4, has markedly antidepressant effect in diabetic rats. Although the authors of the study did not present any data to elucidate its potential mechanism, we would like to put forward a hypothesis in this letter that is highly relevant to this study. Increasing evidence shows depression is often comorbid with somatic symptoms such as chronic back pain, which are primarily due to the suppression of physiological functions of skeletal muscle 5. Interestingly, besides antidepressant and pain-relieving agents, regular exercises are commonly prescribed for depressed patients 6. It is well recognized that regular exercise may exert beneficial effects for the improvement of inactive skeletal muscle functions in depressed patients 7. Additionally, a previous rodent study suggests that animals after regular exercise by treadmill would significantly facilitate the therapeutic effects for depression 8. Furthermore, an excellent study by Agudelo et al. 9 demonstrates that activation of skeletal muscle peroxisome proliferator-activated receptor-gamma coactivator 1α1 (PGC1α1), a critical metabolic coactivator, may strengthen the resilience to chronic stress. The authors of this study only observed the antidepressant effect in the STZ-induced diabetic animal model, but did not further investigate its effects by using conventional depressive animal models. Hence, we inferred that insulin may fail to elicit antidepressant actions in conventional depressive animal models as this model is not associated with disturbances of metabolism in skeletal muscle tissues. Collectively, these findings suggest that improvement of skeletal muscle may exert a beneficial effect for the alleviation of depression-associated symptoms. Currently, mounting studies indicate that the underlying mechanisms of antidepressant agents are mainly attributed to the regulation of abnormalities of monoamine transmitters in the synaptic cleft 10. A previous study performed by Gupta et al. 11 using STZ-induced diabetic animal model shows that insulin successfully exerts therapeutic effects for depression symptoms, which is potentially associated with the effective modulation of the brain serotonin system. Nevertheless, to the best of our knowledge, insulin's molecular is approximately 5808 Dalton, which could not be easily passed through the blood–brain barrier 12. Most importantly, insulin exerting pharmacological benefits is primarily located in skeletal muscles by up-regulating consumption of glucose 13. Although the exact mechanisms of insulin's specific effects for depressive symptoms have not been determined, a possible mechanism that enhancing skeletal muscle function by insulin may facilitate the treatment of depression cannot be ignored. In addition, the notion that deficits in monoamine reuptake system in the synaptic cleft underlie the pharmacological actions of antidepressant agents has generally been accepted by most neuroscientists and psychiatrists. This is not to be taken to mean, however, that all the agents possessing peculiar beneficial effects for depression are solely associated with the conventional notion of monoamine theory. In this regard, we infer that pharmacological benefits of insulin for treating depression are probably related with enhancing effects in skeletal muscle, rather than in the central nervous system. In conclusion, improving skeletal muscle may favour the treatment of depression. And moreover, insulin's pharmacological benefits for depression are probably associated with the up-regulation of inactive state of skeletal muscle induced by diabetes. Future studies are needed to further investigate the possible mechanisms of the comorbidity of depression and diabetes, and fully elucidate insulin's pharmacological property. This study was supported by the Program of Bureau of Science and Technology Foundation of Changzhou (No: CJ20159022) and Major Science and Technology Projects of Changzhou Municipal Committee of Health and Family Planning (No: ZD201505). The authors declared no any potential conflicts of interest.

The Role of Nitric Oxide in the Antidepressant Actions of 5-Aminoimidazole-4-Carboxamide-1-β-D-Ribofuranoside in Insulin-Resistant Mice

Depression-like behaviors in mice subjected to co-treatment of high-fat diet and corticosterone are ameliorated by AICAR and exercise

The Full Capacity of Aicar to Reduce Obesity-Induced Inflammation and Insulin Resistance Requires Myeloid Sirt1

Icariin Exerts an Antidepressant Effect in an Unpredictable Chronic Mild Stress Model of Depression in Rats and is Associated with the Regulation of Hippocampal Neuroinflammation.

A Potential Mechanism Underlying the Antidepressant Effect of Insulin

Nicotinamide, a vitamin B3 ameliorates depressive behaviors independent of SIRT1 activity in mice

Mechanisms underpinning AMP-activated protein kinase-related effects on behavior and hippocampal neurogenesis in an animal model of depression

Berberine and Ginsenoside Rb1 Ameliorate Depression-Like Behavior in Diabetic Rats.

A Focus on ICAM-1, SIRT1 and Nitric Oxide

Effect of AICAR on the antidepressant effect of ketamine

Antidiabetic Drug Metformin Ameliorates Depressive-Like Behavior in Mice with Chronic Restraint Stress via Activation of AMP-Activated Protein Kinase

The Antidepressant-Like Activity of AC-5216, a Ligand for 18kda Translocator Protein (TSPO), in an Animal Model of Diabetes Mellitus

Inhibition of Indoleamine 2,3-Dioxygenase in the Prelimbic and Infralimbic Cortices Exerts Antidepressant Effects Through Different Pathways in ICV-STZ Rats

Antidiabetic drug glyburide modulates depressive-like behavior comorbid with insulin resistance

Activation of Hippocampal IR/IRS-1 Signaling Contributes to the Treatment with Zuogui Jiangtang Jieyu Decoction on the Diabetes-Related Depression

Study on the Mechanism for SIRT1 during the Process of Exercise Improving Depression

Exploring the active components and potential mechanisms of Alpiniae oxyphyllae Fructus in treating diabetes mellitus with depression by UPLC-Q-Exactive Orbitrap/MS, network pharmacology and molecular docking

Noradrenaline activation of hippocampal dopamine D1 receptors promotes antidepressant effects

Indoleamine-2,3-Dioxygenase/Kynurenine Pathway as a Potential Pharmacological Target to Treat Depression Associated with Diabetes

Modulation of depression-related behaviors by adiponectin AdipoR1 receptors in 5-HT neurons